PATENT CLAIM ANALYSIS

Application Number: 16112304
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "133100"]

Abstract:
The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Claim (Index 1):
A method of inhibiting VEGF induced sprouting by contacting cells with a composition comprising a chimeric anti-endoglin antibody and a composition comprising a VEGF antagonist;\n said chimeric anti-endoglin antibody comprising a light chain variable region (V L ) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C L ) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V H ) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

Metadata:
- Claim Count in Document: 133.0
- Percentile: 96.0
- Lexical Diversity: 2.29167
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13485702', '14054446', '15337113', '14838006', '12751907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7749778887672324
- 35 USC 102 Novelty (BERT): 0.5459539997878856
- Combined Prediction Score: 0.7520754998692978
- Mean Citation Score: 385.918738
- Max Citation Score: 422.3443
- Similarity Product: 298.214107694596

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test